These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 34979847)

  • 1. Perforated Duodenal Ulcer Associated with Deferasirox in a Child with β-Thalassemia Major.
    Zahra A; Ragab A; Al-Abboh H; Ismaiel A; Adekile AD
    Hemoglobin; 2021 Sep; 45(5):335-337. PubMed ID: 34979847
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Perforated duodenal ulcer: a rare complication of deferasirox in children.
    Yadav SK; Gupta V; El Kohly A; Al Fadhli W
    Indian J Pharmacol; 2013; 45(3):293-4. PubMed ID: 23833377
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Curative effects and safety of deferasirox in treatment of iron overload in children with β-thalassemia major].
    Gao HY; Li Q; Chen JJ; Chen GF; Li CG
    Zhongguo Dang Dai Er Ke Za Zhi; 2011 Jul; 13(7):531-4. PubMed ID: 21752315
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The deferiprone and deferasirox combination is efficacious in iron overloaded patients with β-thalassemia major: A prospective, single center, open-label study.
    Totadri S; Bansal D; Bhatia P; Attri SV; Trehan A; Marwaha RK
    Pediatr Blood Cancer; 2015 Sep; 62(9):1592-6. PubMed ID: 25820920
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Five Years of Deferasirox Therapy for Cardiac Iron in β-Thalassemia Major.
    Vlachaki E; Agapidou A; Spanos G; Klonizakis P; Vetsiou E; Mavroudi M; Boura P
    Hemoglobin; 2015; 39(5):299-304. PubMed ID: 26177199
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An open-label, multicenter, efficacy, and safety study of deferasirox in iron-overloaded patients with non-transfusion-dependent thalassemia (THETIS): 5-year results.
    Lai YR; Cappellini MD; Aydinok Y; Porter J; Karakas Z; Viprakasit V; Siritanaratkul N; Kattamis A; Liu R; Izquierdo M; Lasher J; Govindaraju S; Taher A
    Am J Hematol; 2022 Aug; 97(8):E281-E284. PubMed ID: 35560253
    [No Abstract]   [Full Text] [Related]  

  • 7. Efficacy and safety of a novel combination of two oral chelators deferasirox/deferiprone over deferoxamine/deferiprone in severely iron overloaded young beta thalassemia major patients.
    Elalfy MS; Adly AM; Wali Y; Tony S; Samir A; Elhenawy YI
    Eur J Haematol; 2015 Nov; 95(5):411-20. PubMed ID: 25600572
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of Deferasirox (Exjade®) in Modulation of Iron Overload in Patients with β-Thalassemia Intermedia.
    Karimi M; Arandi N; Haghpanah S; Ansari S; Azarkeyvan A; Bordbar M; Safaei S
    Hemoglobin; 2015; 39(5):327-9. PubMed ID: 26114738
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative Efficacy and Safety Between Deferiprone and Deferasirox with Special Reference to Serum Ferritin Level and Cardiac Function in Bengali β-Thalassemia Major Children.
    Tripathy I; Panja A; Dolai TK; Mallick AK
    Hemoglobin; 2021 Sep; 45(5):296-302. PubMed ID: 34758688
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined therapy with desferrioxamine and deferiprone in beta thalassemia major patients with transfusional iron overload.
    Daar S; Pathare AV
    Ann Hematol; 2006 May; 85(5):315-9. PubMed ID: 16450126
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy And Tolerability Of Oral Iron Chelator, Deferasirox.
    Tahir A; Hussain SI; Khan HS; Khalil S; Haider SZ; Lodhi MA
    J Ayub Med Coll Abbottabad; 2021; 33(2):207-212. PubMed ID: 34137530
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tolerance induction to deferasirox in a child with transfusion-dependent beta thalassemia.
    Pondrom M; Monpoux F; Rocher F; Gastaut N; Bailly-Piccini C; Poirée M
    Arch Pediatr; 2021 Jan; 28(1):101-103. PubMed ID: 33250331
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of deferasirox for reducing total body and cardiac iron in thalassemia.
    Merchant R; Ahmed J; Krishnan P; Jankharia B
    Indian Pediatr; 2012 Apr; 49(4):281-5. PubMed ID: 21992861
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A 15-years follow-up of deferasirox in beta-thalassaemia major patients with iron overload.
    Wei Z; Yang G; Huang Y; Peng P; Long L; Long Y; Huang X; Zhou X; Lai Y; Liu R
    Br J Haematol; 2020 Nov; 191(3):e81-e83. PubMed ID: 32945527
    [No Abstract]   [Full Text] [Related]  

  • 15. Gastric ulcer in a child treated with deferasirox.
    Bauters T; Mondelaers V; Robays H; Hunninck K; de Moerloose B
    Pharm World Sci; 2010 Apr; 32(2):112-3. PubMed ID: 20063122
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reversible Fanconi syndrome in a pediatric patient on deferasirox.
    Rheault MN; Bechtel H; Neglia JP; Kashtan CE
    Pediatr Blood Cancer; 2011 Apr; 56(4):674-6. PubMed ID: 21298760
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The long-term efficacy and tolerability of oral deferasirox for patients with transfusion-dependent β-thalassemia in Taiwan.
    Chang HH; Lu MY; Peng SS; Yang YL; Lin DT; Jou ST; Lin KH
    Ann Hematol; 2015 Dec; 94(12):1945-52. PubMed ID: 26404899
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Compliance and satisfaction with deferasirox (Exjade®) compared with deferoxamine in patients with transfusion-dependent beta-thalassemia.
    Haghpanah S; Zarei T; Zahedi Z; Karimi M
    Hematology; 2014 Jun; 19(4):187-91. PubMed ID: 24074344
    [TBL] [Abstract][Full Text] [Related]  

  • 19. One-year results from a prospective randomized trial comparing phlebotomy with deferasirox for the treatment of iron overload in pediatric patients with thalassemia major following curative stem cell transplantation.
    Inati A; Kahale M; Sbeiti N; Cappellini MD; Taher AT; Koussa S; Nasr TA; Musallam KM; Abbas HA; Porter JB
    Pediatr Blood Cancer; 2017 Jan; 64(1):188-196. PubMed ID: 27576370
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of deferasirox in reducing and preventing cardiac iron overload in beta-thalassemia.
    Pennell DJ; Porter JB; Cappellini MD; El-Beshlawy A; Chan LL; Aydinok Y; Elalfy MS; Sutcharitchan P; Li CK; Ibrahim H; Viprakasit V; Kattamis A; Smith G; Habr D; Domokos G; Roubert B; Taher A
    Blood; 2010 Mar; 115(12):2364-71. PubMed ID: 19996412
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.